Suryadevara Naveenchandra, Otrelo-Cardoso Ana Rita, Kose Nurgun, Hu Yao-Xiong, Binshtein Elad, Wolters Rachael M, Greninger Alexander L, Handal Laura S, Carnahan Robert H, Moscona Anne, Jardetzky Theodore S, Crowe James E
Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Nat Microbiol. 2024 Aug;9(8):2128-2143. doi: 10.1038/s41564-024-01722-w. Epub 2024 Jun 10.
Human parainfluenza virus type 3 (hPIV3) is a respiratory pathogen that can cause severe disease in older people and infants. Currently, vaccines against hPIV3 are in clinical trials but none have been approved yet. The haemagglutinin-neuraminidase (HN) and fusion (F) surface glycoproteins of hPIV3 are major antigenic determinants. Here we describe naturally occurring potently neutralizing human antibodies directed against both surface glycoproteins of hPIV3. We isolated seven neutralizing HN-reactive antibodies and a pre-fusion conformation F-reactive antibody from human memory B cells. One HN-binding monoclonal antibody (mAb), designated PIV3-23, exhibited functional attributes including haemagglutination and neuraminidase inhibition. We also delineated the structural basis of neutralization for two HN and one F mAbs. MAbs that neutralized hPIV3 in vitro protected against infection and disease in vivo in a cotton rat model of hPIV3 infection, suggesting correlates of protection for hPIV3 and the potential clinical utility of these mAbs.
人副流感病毒3型(hPIV3)是一种呼吸道病原体,可在老年人和婴儿中引发严重疾病。目前,针对hPIV3的疫苗正在进行临床试验,但尚未有疫苗获批。hPIV3的血凝素神经氨酸酶(HN)和融合(F)表面糖蛋白是主要的抗原决定簇。在此,我们描述了针对hPIV3两种表面糖蛋白的天然存在的强效中和性人抗体。我们从人记忆B细胞中分离出7种中和性HN反应性抗体和1种前融合构象F反应性抗体。一种名为PIV3-23的HN结合单克隆抗体(mAb)表现出包括血凝抑制和神经氨酸酶抑制在内的功能特性。我们还阐明了两种HN单克隆抗体和一种F单克隆抗体的中和结构基础。在hPIV3感染的棉鼠模型中,体外中和hPIV3的单克隆抗体可在体内预防感染和疾病,这表明了hPIV3的保护相关因素以及这些单克隆抗体的潜在临床应用价值。